Data as of Q4 2025 (Dec 31, 2025)

Kynam Capital Management, LP

โ€ขCIK: 1907884โ€ขFiling: Q4 2025

**Kynam Capital Management, LP** manages $1.5B across a concentrated portfolio of 36 positions. The firm maintains significant exposure to select names, highlighted by a substantial $219.0M allocation to COGT. Further top holdings include VERA at $173.8M, SNDX at $169.2M, and TCE2 at $161.4M. This structure suggests a focused, high-conviction approach within its investment mandate.

Total AUM
$1.5B
+ $29.4M in options
QoQ Performance
+9.3%
Positions
34
+ 2 options
Top 10 Concentration
73.2%
Latest Filing
Q4 2025

Top Holdings Allocation

COGT
VERA
SNDX
TCE2
PCVX
COGT14.6%
VERA11.6%
SNDX11.3%
TCE210.8%
PCVX9.0%
BCRX4.9%
VRDN3.1%
TYRA2.7%

๐Ÿ“ˆ Biggest Buys

CTMX
CYTOMX THERAPEUTICS INC
+145.9%
2.6% of portfolio
KALV
KALVISTA PHARMACEUTICALS INC
+198.8%
2.0% of portfolio
CGEM
CULLINAN THERAPEUTICS INC
+35.3%
2.2% of portfolio
BHVN
BIOHAVEN LTD
NEW
0.5% of portfolio
STRO
SUTRO BIOPHARMA INC
NEW
0.4% of portfolio

๐Ÿ“‰ Biggest Sells

VRDN
VIRIDIAN THERAPEUTICS INC
-66.8%
3.1% of portfolio
COGT
COGENT BIOSCIENCES INC
-21.8%
14.6% of portfolio
CGON
CG ONCOLOGY INC
-52.8%
2.6% of portfolio
BEAMCALL
BEAM THERAPEUTICS INC
-62.8%
1.7% of portfolio
WVE
WAVE LIFE SCIENCES LTD
-52.4%
2.5% of portfolio

Sector Breakdown

Other100.0%

๐Ÿšช Exited Positionssold since Q3 2025

UTH
UNITED THERAPEUTICS CORP DEL
SOLD
$20.0M
IRWD
IRONWOOD PHARMACEUTICALS INC
SOLD
$7.2M
โ€”
UROGEN PHARMA LTD
SOLD
$6.9M
โ€”
SUTRO BIOPHARMA INC
SOLD
$4.4M
EWTX
EDGEWISE THERAPEUTICS INC
SOLD
$4.1M

Changes from Q3 2025

NEW6 new positions
โ†‘4 increased
โ†“23 decreased

Historical Filings

Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023